FDA rejects Omeros transplant drug over difficulties estimating its effect

There will be no miraculous escape for Omeros. Weeks after the FDA flagged deficiencies with the filing for approval of a stem cell transplant drug, the agency has issued the complete response letter (CRL) foreshadowed by its earlier communication.